Key Insights

Highlights

Success Rate

91% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

6.3%

2 terminated out of 32 trials

Success Rate

91.3%

+4.8% vs benchmark

Late-Stage Pipeline

16%

5 trials in Phase 3/4

Results Transparency

33%

7 of 21 completed with results

Key Signals

7 with results91% success

Data Visualizations

Phase Distribution

26Total
Not Applicable (9)
Early P 1 (1)
P 1 (2)
P 2 (9)
P 3 (2)
P 4 (3)

Trial Status

Completed21
Unknown4
Terminated2
Not Yet Recruiting2
Recruiting1
Active Not Recruiting1

Trial Success Rate

91.3%

Benchmark: 86.5%

Based on 21 completed trials

Clinical Trials (32)

Showing 20 of 20 trials
NCT07549828Not ApplicableNot Yet Recruiting

Sebum Metabolomics and Lipidomics for Clinical Applications

NCT07404033Phase 1Not Yet RecruitingPrimary

ZYG24002 Lotion to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Adult Patients With Mild to Moderate Seborrheic Dermatitis

NCT07428915Completed

Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists

NCT07063615Not ApplicableActive Not RecruitingPrimary

A Clinical Study to Assess the Safety and Effectiveness of Scalp Cream for Symptom Relief and Microbiome Balance in Mild-moderate Seborrheic Dermatitis Patients.

NCT07297446CompletedPrimary

Phenotypic and Functional Profile of Peripheral Blood Lymphomonocytes in Seborrheic Dermatitis.

NCT05319444Not ApplicableSuspended

Cleansing Device for the Treatment of Scalp and Hair Conditions

NCT05787860Phase 2CompletedPrimary

Ruxolitinib in Seborrheic Dermatitis

NCT06013371Phase 2TerminatedPrimary

PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea

NCT05942248Not ApplicableRecruiting

The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis

NCT04445987Phase 2CompletedPrimary

Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

NCT04472546Not ApplicableCompleted

Use of the SpiderMass for in Vivo Analysis of the Skin in Five Chronic Inflammatory Dermatosis

NCT01315951Not ApplicableTerminatedPrimary

Petrolatum's Effect on Initial Symptoms of Nonscalp Seborrheic Dermatitis and Preventing Exacerbation

NCT04973228Phase 3CompletedPrimary

Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)

NCT04091646Phase 2CompletedPrimary

Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

NCT05105139CompletedPrimary

Study to Evaluate the Safety of Sebryl® and Sebryl Plus® in Seborrheic Dermatitis and Psoriasis of Scalp

NCT00403559Phase 2CompletedPrimary

A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis

NCT03567980Phase 4CompletedPrimary

A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis

NCT03114111Early Phase 1CompletedPrimary

Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis

NCT03807453Completed

Comparison of Scalp Microbiota of the Psoriasis and Seborrheic Dermatitis Patients

NCT03688971Phase 2UnknownPrimary

Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis

Scroll to load more

Research Network

Activity Timeline